GW Pharma (GWPH) Tops Q2 EPS by 61c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
GW Pharma (GWPH) PT Raised to $183 at Oppenheimer Due to Eipidolex Approval and Long-Term Growth Potential
August 4, 2020 10:02 AM EDTOppenheimer analyst Esther Rajavelu raised the price target on GW Pharma (NASDAQ: GWPH) to $183.00 (from $166.00) while maintaining an Outperform rating citing Epidiolex now also approved for TSC, long-term value growth at GWPH, COVID impact, conservative assumptions show that GWPH is undervalued, and TSC label... More
GW Pharma (GWPH) PT Raised to $164 at H.C. Wainwright
August 4, 2020 6:14 AM EDTH.C. Wainwright analyst Douglas Tsao raised the price target on GW Pharma (NASDAQ: GWPH) to $164.00 (from $161.00) while maintaining a Buy rating.... More
